The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology

What does this source report?

Reviews liver polypeptide complex Ventvil and KEDA/Livagen in experimental fibrosis and hepatitis, with immune and antioxidant outcomes.

Population and setting

Animal and in-vitro liver pathology models

Evidence type

Review

Preparation

See the original report; formulation details require verification.

Source language

Russian

Title provenance

Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

• Extract and tetrapeptide are separate interventions.
• This is a review of experimental models, not a clinical hepatitis treatment trial.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.

Open original source or index record ↗

Cite and trace this record

Original source: Kuznik BI, Khasanova NB, Ryzhak GA, Mezsheriakova IE, Khavinson VK. The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology Adv Gerontol 33(1):159-164. PMID 32362099 2020.

Molekul research summary: https://molekul.io/research/bio-32362099. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Related compound profiles